



(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/26 (2006.01)
A61K 47/40 (2006.01) A61K 31/437 (2006.01)
A61K 47/42 (2006.01) A61P 1/04 (2006.01)

(21) International Application Number:

PCT/IB2024/050869

(22) International Filing Date:

31 January 2024 (31.01.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2023-0013947 01 February 2023 (01.02.2023) KR

(71) Applicant: **ONCONIC THERAPEUTICS INC.**
[KR/KR]; 11F, 12 Teheran-ro 26-gil, Gangnam-gu, Seoul
06236 (KR).

(72) Inventors: **KIM, Aeri**; 309-402, 177 Migeum-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13628 (KR). **YUN, Jungmin**; 302-604, 126 Seongbok 2-ro, Suji-gu, Yongin-si, Gyeonggi-do 16851 (KR). **KIM, John**; B-1004, 57 Horyeong-ro 72-gil, Seocho-gu, Seoul 06732 (KR).


(74) Agent: **AHN, So Young**; 3rd Fl., 416, Nonhyeon-ro, Gangnam-Gu, Seoul 06224 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: INJECTABLE COMPOSITION, PHARMACEUTICAL FORMULATION INCLUDING THE SAME, AND METHOD FOR PREPARING THE COMPOSITION

FIG. 1



(57) Abstract: The present invention relates to an injectable composition, a pharmaceutical formulation comprising the same, and a method for preparing the same. The injectable composition according to the present invention comprises: azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl}methanone citrate as active ingredient; and SBE- β -CD.

Published:

— with international search report (Art. 21(3))